Drug intelligence / Profile preview

AIT-034

Development stage: Discontinued
Lead developer: Assertio
Modality: Small Molecules

Overview

AIT-034 is a distinct chemical analog of hypoxanthine and pyrollidone that was developed as a small molecule drug for the treatment of cognitive disorders, including dementia. In animal studies, it has been shown to enhance memory and reverse memory deficits in severely impaired animals that do not respond to Neotrofin. Unlike Neotrofin, AIT-034 does not induce nerve growth factor (NGF) production, suggesting a different mechanism of action. The drug was investigated as a potential therapy for Alzheimer's disease and other dementias but development has been discontinued[2][3][5].

Beyond the preview

Go deeper on AIT-034.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIT-034.

Explore the full profile